Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are 18 years of age or older at the time treatment begins
• People who have a type of B-cell non-Hodgkin lymphoma (a blood cancer) confirmed by a tissue test, specifically follicular lymphoma (but not a subtype called grade 3B), mantle cell lymphoma, or marginal zone lymphoma
• People who have measurable disease in their lymph nodes
• People who are willing to have a biopsy (a small tissue sample taken) from a lymph node or other affected area
• People whose lymphoma has come back after treatment, has stopped responding to standard treatment, or for whom no standard treatment exists
• People who have already received at least one course of standard treatment, which must have included a drug called rituximab
• People who are expected to live for at least 12 weeks
• People who are reasonably well and able to carry out daily activities — assessed using a standard medical scale rated 0 to 2 (confirm with trial site)
• People whose cancer cells carry a marker called CD20 on their surface
• People whose blood counts and organ function results fall within the ranges required by the trial (confirm with trial site)

Who may not be able to join:

• People who have had a bone marrow or stem cell transplant from a donor within the past 12 months
• People who currently have active graft versus host disease (a condition where donor cells attack the body after a transplant)
• People who have lymphoma affecting the brain, spinal cord, or the fluid surrounding them
• People whose lymphoma has changed (transformed) from a slower-growing type of lymphoma
• People who have a condition called Waldenström's Macroglobulinemia, or follicular lymphoma grade 3B
• People who need high daily doses of steroid medication (such as prednisolone above 10 mg per day) during the trial, except as a pre-medication (confirm with trial site)
• People who are known or suspected to have an allergy to rituximab or the trial drug BI-1206
• People who have a specific type of protein build-up in the heart or kidneys called cardiac or renal amyloid light-chain amyloidosis
• People who have recently received certain treatments, including: chemotherapy or certain targeted drugs within 2 weeks, radiation therapy within 4 weeks (except for specific symptom relief), immunotherapy within 8 weeks, or previous treatment with a class of drugs called BTK inhibitors (for those in a specific part of the trial)
• People who are still experiencing significant side effects from previous treatments
• People who are pregnant, breastfeeding, or able to become pregnant
• People who have had major surgery from which they have not yet fully recovered
• People who have a serious non-cancer illness, including an active infection currently being treated with antibiotics, antifungal, or antiviral medicines
• People who test positive for hepatitis B, hepatitis C, or HIV
• People who have an active autoimmune disease (where the immune system attacks the body)
• People who have significant heart failure or a history of serious heart disease (classed as Grade III or IV on a standard heart health scale)
• People who currently have another type of active cancer

Important: Always verify eligibility with the trial site directly before applying.